Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.
Full Title of Study: “High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology”
- Study Type: Observational
- Study Design
- Time Perspective: Other
- Study Primary Completion Date: September 23, 2020
Clinical Trial Outcome Measures
- Number of cumulated deep venous thrombosis among the hospitalization
- Time Frame: Day 7 after admisssion
Participating in This Clinical Trial
- Age>18 years
- COVID-19 confirmed with RT-PCER and/or chest CT-scan
- Acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke.
- Other neurovascular diseases
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
- Lead Sponsor
- University Hospital, Strasbourg, France
- Provider of Information About this Clinical Study
- Overall Contact(s)
- Olivier ROUYER, MD, 33 3 88 12 87 50, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.